Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration

PURPOSE: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular macular degeneration treated with intravitreal Aflibercept. METHODS: A systematic search was performed in the NCBI/PubMed database to identify pro- and retrospective studies retrieved by the key term...

Descripción completa

Detalles Bibliográficos
Autor principal: Garweg, Justus G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650619/
https://www.ncbi.nlm.nih.gov/pubmed/31409968
http://dx.doi.org/10.2147/OPTH.S185756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650619/
https://www.ncbi.nlm.nih.gov/pubmed/31409968
http://dx.doi.org/10.2147/OPTH.S185756

Ejemplares similares